Patheon to make tough cuts at U.K. facility; Charles River CEO downplays asset transfer deals;

 @NesaNFierce: Monkey see, monkey ... don't. MPI Research is getting lots of flack from the USDA and an animal rights group over animal mistreatment. | Follow @NesaNFierce

> Struggling Canadian CMO Patheon will need to eliminate more than 90 jobs and downsize production at its facility in Swindon, U.K., after failing to sell it. More

> Charles River CEO James Foster downplays his interest in asset transfer deals, saying they don't make "rational sense," especially if the potential deals are outside his company's vicinity. News

> While pharma and clinical jobs in the Americas fell 10%, they went up 25% in Europe, according Ed Silverman of Pharmabiz. Article

> INC Research has expanded its business relationship with Medidata Solutions by attaining three new accreditations for Medidata's clinical cloud platform. Release

And Finally… ACRO India sounds off to FierceCRO about a Pharmabiz report that says ACRO India helped spur the video documentation of clinical trials in the country. But while the umbrella organization denies ever making any comments to Pharmabiz, it neither confirmed nor denied videotaping reports. Story

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.